Folia Health Launches FSGS PULSE Study to Generate a More Complete Understanding of FSGS Disease Burden and Treatment

Trial StartNeutral

AI Analysis

Summary

Folia Health launches the FSGS PULSE Study to evaluate real-world symptoms, treatment impact, and quality of life outcomes in focal segmental glomerulosclerosis patients.

Clinical Trial Data

Importance:2/10

Sentiment:

0.00

clinical trialFSGSreal-world evidencequality of life

Related Companies

$IBO $HIT $WHEN

Read the original article

Published by GlobeNewswire Clinical Studies on August 11, 2026 2:00 PM

Read Original